Epidemiology of psoriasis in hard-to-treat body locations: data from the Danish skin cohort

Egeberg, Alexander; See, Kyoungah; Garrelts, Alyssa; Burge, Russel

doi:10.1186/s12895-020-00099-7

Cited by 61 publications

(59 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This can be illustrated for specific body sites, such intertriginous skin, scalp, or nails, to provide important clinical insights into differential treatment responses to targeted psoriatic therapies. Many clinical trials and real-world studies have previously shown that special sites of skin (e.g., scalp, nails, joints, palms/soles) do not always respond in line with the observed skin response [ 18 , 19 ]. Varied individual response could be related to treatment compliance, natural fluctuations in a patient’s immune response, and/or external triggers of disease, such as trauma, infections, scratching and stress.…”

Section: Discussionmentioning

confidence: 99%

Dynamic Visual Representation of Clinical Efficacy of Ixekizumab in Psoriasis

Hawkes

See

Burge

et al. 2021

Dermatol Ther (Heidelb)

Self Cite

View full text Add to dashboard Cite

Introduction: Ixekizumab, a high-affinity monoclonal antibody that selectively targets interleukin-17A, is an approved treatment for plaque psoriasis. This study aimed to use animated visualizations as a tool to simplify complex data from ixekizumab clinical trials. Methods: Animated visualizations were developed to show outcomes from ixekizumab clinical trials and a Bayesian network meta-analysis of 11 approved biologics. The visualizations simultaneously highlighted both aggregate scores and the individual progression of patients over the course of treatment. Results: The animations provided key messages and information from the complex data in efficient and scientific ways that were also visually pleasing and simple to understand. The animations highlighted (1) rapid reduction in disease severity from baseline; (2) sustained efficacy of ixekizumab in the treatment of skin and nail psoriasis; (3) side-by-side comparisons of treatment efficacy and clinical improvement across trials; (4) simultaneous visual presentation of individual results with summary response over time; and (5) indirect comparison of relative treatment effects with other biologics based on Bayesian network meta-analysis. Conclusion:The rapid and sustained efficacy of ixekizumab in the treatment of psoriasis was demonstrated using multiple dynamic visualizations with different clinical endpoints. Animated visualizations provided a simpler and more comprehensive understanding of complex data than conventional static figures.

show abstract

Section: Discussionmentioning

confidence: 99%

Dynamic Visual Representation of Clinical Efficacy of Ixekizumab in Psoriasis

Hawkes

See

Burge

et al. 2021

Dermatol Ther (Heidelb)

Self Cite

View full text Add to dashboard Cite

show abstract

“…Literature review shows that men and women are equally affected by nail psoriasis, and its prevalence increases with the age of the study population [26]. Results from a Danish skin cohort with a total of 4016 adults with psoriasis showed that the most frequently affected hard-to-treat area was the scalp (43.0%), followed by the face (29.9%), nails (24.5%), soles (15.6%), genitals (14.1%), and palms (13.7%) [27]. Similarly to our study results, higher prevalence was generally seen with increasing psoriasis severity and patients with involvement of certain hard-totreat areas such as hands, feet, and genitals had clinically relevant DLQI impairments.…”

Section: Discussionmentioning

confidence: 99%

Untitled

2021

BJSTR

View full text Add to dashboard Cite

on quality of life. Thus, patients with any type of psoriasis require an assessment of the severity of the disease, the impact of the disease on physical, psychological and social condition, diagnosis of the existence of psoriatic arthritis or other comorbidities. Overall assessment of the patient, assessment of the affected body surface, nail damage, affected areas with high impact and difficult to treat, or any systemic disorder such as fever, malaise, which are common in unstable forms of psoriasis such as erythroderma or generalized pustular psoriasis [1].Psoriasis is a chronic, multisystemic disease with many comorbidities, which is often difficult to treat, and some cases may be refractory to treatment. Total eradication of plaques is difficult to achieve, and the remission time is short. Recurrence is inevitable and is often preceded by poor adherence to topical therapy. Forms of gouttate psoriasis may resolve spontaneously or may progress to chronic plaque psoriasis. Erythrodermic psoriasis and generalized ARTICLE INFO ABSTRACTBackground: The epidemiological profile of psoriasis may show the great psychoemotional impact through hard-to-treat body locations. Methods: We performed a retrospective study of 527 patients with psoriasis in the Dermatological Clinic of the Emergency County Clinical Hospital "Saint Spiridonov", Iasi in order to establish the frequency of major forms of psoriasis and describe the characteristics such as age group and special impairment distribution. Results:The frequency of scalp psoriasis was significantly higher in patients aged ≤18 years (51.61% compared to 32.73% aged 19-49 years, Z=2.01, p=0.02; compared to 31, 66% aged between 50-69 years, Z=2.22, p=0.01 or compared to 29.17% aged ≥ 70 years, Z=2.18, p=0.01). Facial psoriasis was significantly higher in patients aged ≤18 years (12.9% compared to 4.24% aged 19-49 years, Z=1.92, p=0.027, compared to 1.16 % aged between 19-49 years, Z=4.02, p <0.00001 and compared to 1.39% aged ≥ 70 years, Z=2.49, p=0.006). It was also observed that the frequency of genital area involvement was significantly high (38.1%, Z = 1.77, p = 0.038). Conclusion:The burden of disease may be due to high frequency of hard-totreat body locations such as the facial and scalp regions at early age and genital area involvement has a negative impact on their quality of life.

show abstract

“…Nail involvement on fingers and/or toes is frequent in psoriasis, with 25% [1] to 41% [2] of patients affected. It is also a marker of increased disease severity of psoriasis and psoriasis arthritis [3][4][5].…”

Section: Quality Of Life In People With Nail Psoriasismentioning

confidence: 99%

Nail Psoriasis and Quality-of-Life Measurement in Clinical Trials: Call for the Use of Nail-Specific Instruments

2021

View full text Add to dashboard Cite

Nail involvement is frequent in people with psoriasis. It can considerably impair health-related quality of life (HRQoL) beyond the impairments due to other psoriasis symptoms, for example, because patients feel ashamed of visible nail defects or because of the functional impairment in manual activities and walking. In clinical trials on nail psoriasis, it is therefore crucial to assess whether the treatment reduces HRQoL impairments that are specific to nail psoriasis. For this purpose, two validated patient questionnaires are available, the Nail Psoriasis Quality of Life Scale (NPQ10) and the Nail Assessment in Psoriasis and Psoriatic Arthritis-Quality of Life (NAPPA-QOL). The ten-item NPQ10 has the advantage of being short and thus quick to administer. The 20-item NAPPA-QOL, in contrast, assesses the different dimensions of HRQoL which is considered a multi-dimensional construct. Yet most randomized controlled trials on nail psoriasis do not evaluate HRQoL improvement. If they do, a number of different instruments are used, most of which are not nail specific. This makes comparison of trial outcomes difficult. Harmonizing the measurement of HRQoL in future clinical trials on nail psoriasis would improve comparability across studies and would also enhance the reliability of meta-analyses. Key PointsPatients with nail psoriasis have specific quality-of-life impairments as compared to patients with psoriasis in general.Quality-of-life impairments that stem specifically from nail involvement in psoriasis should be measured with nail psoriasis-specific and validated questionnaires.In order to enable comparisons between clinical studies, harmonization of measurement instruments to be used across trials is needed.

show abstract

Epidemiology of psoriasis in hard-to-treat body locations: data from the Danish skin cohort

Cited by 61 publications

References 36 publications

Dynamic Visual Representation of Clinical Efficacy of Ixekizumab in Psoriasis

Dynamic Visual Representation of Clinical Efficacy of Ixekizumab in Psoriasis

Untitled

Nail Psoriasis and Quality-of-Life Measurement in Clinical Trials: Call for the Use of Nail-Specific Instruments

Contact Info

Product

Resources

About